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Abstract
Acne vulgaris is a chronic skin disease that develops as a result of inflammation of the 
pilosebaceous unit and its clinical course is accompanied by comedones, papules, pus-
tules, and nodules. A different group of disease, which is clinically similar to acne vul-
garis but with a different etiopathogenesis, is called “acneiform eruptions.” In clinical 
practice, acneiform eruptions are generally the answer of the question “What is it if it 
is not an acne?” Although there are many subgroups of acneiform eruptions, drugs are 
common cause of acneiform eruptions, and this clinical picture is called “drug-induced 
acneiform eruptions.” There are many drugs related to drug-induced acneiform erup-
tions. Discontinuation of the responsible drug is generally sufficient in treatment.
Keywords: acne, cutaneous toxicities, drug-induced acneiform eruptions, papule, 
pustule
1. Introduction
Acne vulgaris (AV) is a common skin disorder, which affects almost 85% of individuals at 
least once during life time. Although AV pathogenesis is not clearly understood yet, increased 
sebum production, androgenic hormones, ductal hypercornification, abnormal follicular 
keratinization, colonization of Propionibacterium acnes (P. acnes), inflammation, and genetic 
predisposition have been suggested to enhance acne development [1]. Hormone-dependent 
juvenile acne is a more frequent subgroup, whereas mechanical and drug-induced acne, 
which are particularly encountered during adulthood, are associated with the drug use with 
specific underlying etiologies [2]. Acneiform drug eruptions represent a sudden-onset clinical 
presentation, where the comedones are not observed [3]. In addition, several drugs are known 
to be associated with drug-induced acneiform eruptions [2]. In particular, the development of 
new target-specific molecules in the field of oncology, such as epidermal growth factor recep-
tor inhibitors (EGFRIs), has caused a significant increase in the incidence of drug-induced 
acneiform eruptions [2, 3] (Table 1).
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Hormones
Oral, inhaled and topical corticosteroids
Corticotropin (ACTH)
Androgens and anabolic steroids
Hormonal contraceptives
Other hormones
- thyroid-stimulating hormone, danazol
Neuropsychotherapeutic drugs
Tricyclic antidepressants
- amineptine, maprotiline, imipramine
Lithium
Antiepileptic drugs
- hydantoin, lamotrigine, valproate
Antipsychotics
- aripiprazole
Selective serotonin reuptake inhibitors
Vitamins
Vitamins B1, B6, B12
Cytostatic drugs
Dactinomycin (actinomycin D)
Azathioprine, thiourea, thiouracil
Immunomodulating molecules
Cyclosporine
Sirolimus
Others
- topical tacrolimus, topical pimecrolimus
Antituberculosis drugs
Isoniazid
Rifampin (rifampicin)
Ethionamide
Halogens
Iodine
Bromine
Chlorine
Others: halothane gas, lithium
Miscellaneous
Dantrolene
Quinidine
Antiretroviral therapy
Targeted therapies
Epidermal growth factor receptor inhibitors (EGFR inhibitors)
- erlotinib, gefitinib, imatinib
Epidermal growth factor receptor monoclonal antibodies
- cetuximab, panitimumab
TNFa inhibitors
- lenalidomide
- infliximab
- adalimumab
G-CSF
- vemurafenib
VEGF inhibitor
- bevacizumab
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This section focuses on the clinical and differential characteristics of drug-induced acneiform 
eruptions, drugs which may lead to this clinical presentation, and available treatment options 
in the light of the current literature data.
2. Clinical characteristics
Drug-induced acneiform eruptions may occur during childhood, adolescence, and adult-
hood. Lesions typically appear as monomorphic inflammatory papules and pustules with-
out comedones or cysts. Papulopustular lesions usually involve on face, neck, chest, and 
upper back and can be extended beyond the seborrheic regions. Although its clinical 
course varies between patients, it often has a rapid onset without a previous history of AV. 
Papulopustular lesions may develop weeks, months, or even years after the exposure of 
the causative drug, and lesions may continue developing after the discontinuation of the 
drug [1].
3. Diagnosis and differential diagnosis
Diagnosis of drug-induced acneiform eruptions is not based on any specific criteria. There are 
some clue signs that may be helpful to differentiate this clinical presentation from other com-
mon skin disorders. The sudden onset and monomorphic character of the lesions, absence of 
comedones in general, the presence of lesions in regions where acne vulgaris is not commonly 
present, the development of lesions at any age, and the presence of a history of drug use were 
Proteasome inhibitor
- bortezomib
Histone deacetylase inhibitor
- vorinostat
EGF, epidermal growth factor; TNFa, tumor necrosis factor-a; VEGF, vascular endothelial growth factor; G-CSF, 
granulocymte colony-stimulating factor.
Table  1. Drugs involved with acneiform eruptions [2, 3].
Drug-induced acneiform eruption Acne vulgaris
Monomorphic lesions, lacking comedones, and cysts Polymorphic lesions (mixture of comedones, papules, 
pustules, and nodules)
Extension beyond seborrheic areas to include arms, trunk, 
lower back, and genitalia
Localized primarily on seborrheic areas such as the face 
and neck and, less commonly, on the upper back, chest, 
and arms
Unusual age of onset (>30 years) Commonly affects adolescents and young adults
Resistant to conventional acne therapy Improves with conventional acne therapy
Onset after drug initiation, improvement after drug 
withdrawal, or reoccurrence after drug reintroduction
No causative relationship to drug therapy
Table 2. Drug-induced eruption versus acne vulgaris [1, 3].
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the supportive findings and clues in the diagnosis. Clues, which may be helpful to differenti-
ate drug-induced acneiform eruptions from idiopathic AV, are summarized in [1, 3] (Table 2). 
Cases that represent a diagnostic challenge should be extensively questioned with respect to 
medication history. Temporal relationship between the medication use and symptom devel-
opment is very important [1].
4. Causative drugs
4.1. Hormones
4.1.1. Corticosteroids and corticotropin (ACTH)
Acneiform eruptions induced by the use of systemic corticosteroid therapy were first reported 
in 1950s [4]. Exposure to oral [5], intravenous [6], topical [7], or inhaled steroids [8] may result 
in or exacerbate acne. Development of acneiform eruptions was also reported during cortico-
tropin therapy [4]. Perioral dermatitis is a form of acneiform eruption which may develop due 
to the use of highly potent corticosteroids [9]. During topical corticosteroid therapy, lesions 
may not become erythematous due to anti-inflammatory effects [10]. Although lesions usu-
ally begin to develop within 2–4 weeks after the administration of oral or topical therapy, they 
can also occur months after therapy. Dose, treatment duration, and individual factors may 
significantly affect the clinical presentation [2].
4.1.2. Androgens and anabolic steroids
Androgens are known to cause adolescent acne by increasing sebum production. In addi-
tion, anabolic steroids and synthetic hormones, which have androgenic activities, also show 
similar effects on the sebaceous glands [11]. In a prospective study, Fyrand et al. reported an 
increase in acne incidence among puberty-aged men who were administered injectable tes-
tosterones [12]. Moreover, acne incidence was also found to be higher among young athletes 
who used anabolic-androgenic steroids to increase their muscle mass [13].
4.1.3. Hormonal contraceptives
Hormonal contraceptive agents may induce or exacerbate acne [2]. A previous study demon-
strated that 26.8% of women who used contraceptive etonogestrel implants developed acne 
[14]. Additionally, women who were placed a levonorgestrel-releasing intrauterine device 
developed inflammatory papular lesions 1–3 months after the procedure [15].
4.1.4. Other hormones
Danazole is an antigonadotropic agent used for the treatment of hereditary angioedema and 
endometriosis. Development of nodulocystic acneiform eruptions was previously reported 
in a woman receiving danazole therapy for endometriosis [16]. Thyroid hormones may also 
rarely result in acneiform eruptions [17].
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4.2. Neuropsychotherapeutic drugs
4.2.1. Tricyclic antidepressants
Amineptine is one of the non-halogenated tricyclic antidepressants [3]. Amineptine may 
result in fast-onset acneiform eruptions consisting of macrocysts, microcysts, and comedo-
nes, months or even years after the initiation of therapy. Severity of the disease is associated 
with the dose and duration of therapy [1]. Amineptine and its products were found in serum, 
urine, and skin lesions, and histological examinations showed that this drug may result in 
keratinizing syringometaplasia in neutrophilic eccrine hidradenitis and eccrine glands [18]. 
Tricyclic antidepressants such as maprotiline [19] and imipramine [20] are also known to 
cause acneiform eruptions.
4.2.2. Lithium
Lithium may cause fast-onset inflammatory lesions on face, axilla, groin, arms, and but-
tocks. Lithium-induced acneiform eruptions are more frequent among men and those 
who are allergic to lithium [21]. No direct relation was shown between dose and severity 
of acne [2].
4.2.3. Antiepileptic drugs
Several antiepileptic agents were associated with drug-induced acneiform eruptions [22]. 
Phenytoin [23], phenobarbital [22], lamotrigine [24], and valproate [25] are among the most 
common culprits. Phenytoin is known to cross the placenta and cause acneiform eruptions, 
hypertrichosis, and gingival hyperplasia [26].
4.2.4. Aripiprazole
Aripiprazole is a quinolone-derivative antipsychotic drug reported to induce papulopustular 
acneiform eruptions in a patient 10 days after the initiation of therapy [27].
4.2.5. Selective serotonin reuptake inhibitors
All selective serotonin reuptake inhibitors may cause acneiform eruptions on the face, chest, 
and back regions [28].
4.3. Vitamins B1, B6 and B12
Acneiform eruptions characterized by monomorphic inflammatory papulopustular lesions 
localized on the face, neck, upper back, and chest may develop after the B12 injection therapy 
(Figure 1). The reason underlying this is not clearly known; however, the lesions rapidly 
disappear after discontinuation of therapy [29]. Several pharmaceutical preparations also 
involve B1 (thiamine) and B6 (pyridoxine) vitamins in addition to B12; however, the role of 
these vitamins in acne development is still controversial [30].
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4.4. Cytostatic drugs
4.4.1. Dactinomycin (actinomycin D)
Dactinomycin, which is a cytostatic agent used for the treatment of solid tumors, is asso-
ciated with acneiform eruptions. It has been suggested that dactinomycin induces acnei-
form eruptions through its androgenic characteristics and due to its tricyclic chemical 
structure [1].
4.4.2. Other cytostatic drugs
Although rare, the development of acneiform eruptions has been reported upon the use of 
azathioprine, thiourea, and thiouracil; however, the evidences are still limited [17, 31].
4.5. Immunomodulating molecules
4.5.1. Cyclosporine
Cyclosporine is an agent with immunosuppressive activity and it is used after organ trans-
plantations and for the treatment of psoriasis and atopic dermatitis. As it is a highly lipophilic 
Figure 1. Inflammatory papules and pustules on the chest after B12 injection treatment.
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compound, it can potentially be eliminated through the sebaceous glands. Therefore, cyclo-
sporine may induce acneiform eruptions by affecting the pilosebaceous follicle structures and 
functions [31].
4.5.2. Sirolimus
Sirolimus, which is an immunosuppressive agent used after organ transplantation, can result 
in acneiform eruptions [32]. Sirolimus is believed to exert toxic effects on the follicles and alter 
the sebum production and synthesis of epidermal growth factor (EGF) and testosterone [33]. 
In a prospective French study, acneiform eruptions were reported to develop in 46% of 80 
patients who received sirolimus therapy after renal transplantation [34].
4.5.3. Other immunosuppressants
Tacrolimus is a macrolide-derivative agent with T-cell-specific immunosuppressive activity 
which blocks calcineurin-dependent-signaling pathway [3]. There are case reports indicating 
that topical tacrolimus [33] and pimecrolimus [35] may result in facial acne.
4.6. Antituberculosis drugs
4.6.1. Isoniazid
Isoniazid (INH) is a drug used for the treatment and prophylaxis of tuberculosis. It has been 
suggested that INH more easily results in acneiform eruptions in patients with slow acety-
lating phenotypes [3]. Previously, it was reported that acneiform eruptions might develop 
even 18 months after the initiation of INH therapy and disappear after the discontinuation of 
therapy [36].
4.6.2. Rifampin
Rifampin was associated with chronic papular acneiform eruption on face, neck, and shoul-
ders, developing 5 weeks after the treatment onset [37].
4.6.3. Ethionamide
Ethionamide is an agent used for the treatment of tuberculosis and is associated with the 
development of acneiform eruptions [38].
4.7. Halogens
Iodide, bromide, and chloride are salt-containing drugs which result in iododerma, bromo-
derma, and chloracne, respectively. It has been suggested that these drugs induce acneiform 
eruptions, as they are eliminated via the sebaceous glands [1].
4.7.1. Iodine
Iododerma refers to the skin eruptions with different clinical presentations caused by oral, 
parenteral, or topical iodine administration. Lesions may be papular, pustular, or vesicular; 
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however, lesions in erythematous, urticarial, froncular, carbuncular, bullous, vegetating, or 
ulcerating pattern can also develop. Lesions beginning at the seborrheic region may extend 
to the whole body [2]. Although its pathogenesis is unclear, a suggested hypothesis includes 
cell-mediated immune reaction, inflammatory mechanism, and idiosyncratic reactions [39]. 
Discontinuation of iodine therapy is usually sufficient for symptom recovery, whoever the 
use of topical or systemic steroids may become necessary in severe cases [1].
4.7.2. Bromine
Although bromoderma is defined as skin eruption induced by bromide intoxication, it is 
not frequent at the present. Currently, several drugs with sedative, anti-epileptic, spasmo-
lytic, and expectorant activities contain bromide [40]. Bromoderma clinically resembles 
iododerma and its diagnosis can be confirmed by increased serum and urine levels of 
bromide [41].
4.7.3. Chlorine
Acneiform eruptions may develop due to skin exposure to various industrial chemicals such 
as chlorine and its products. These chlorinated hydrocarbons result in the presentation of 
chloracne, characterized by cysts, pustule, folliculitis, and comedones [42]. Lesions usually 
develop at malar, postauricular, axillary, and genital regions, but may extend further [43]. 
Chloracne treatment is challenging and the lesions may continue developing for a long time, 
despite avoiding exposure to chloracnegens [44].
4.7.4. Other agents
Halothane is a halogenated anesthetic gas which may result in the development of acne-
iform eruptions hours after the exposure of the administering health-care personnel [45].
Lithium was reported to cause halogenoderma-like eruptions in two cases in the literature [46].
4.8. Miscellaneous drugs
Dantrolene is a muscle relaxant used for the treatment of spasticity. Dantrolene-induced acne 
consists of blackheads, comedones, cysts, pustules, and abscesses, and the lesions particularly 
localize at the regions exposed to chronic trauma, friction, and pressure. Lesions may develop 
6 months to 4 years after the treatment onset [1].
Quinidine [47] and antiretroviral therapy [48] were also reported to cause acneiform eruptions.
4.9. Targeted therapies
Targeted therapies refer to a special group of medicines interacting with specific key mol-
ecules that play roles in the pathophysiology of inflammatory and tumoral diseases. This 
group of therapeutic agents includes tyrosine kinase inhibitors such as gefitinib, erlotinib, and 
imatinib, monoclonal antibodies such as cetuximab, panitumumab, and infliximab, soluble 
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antibodies such as etanercept, transcription modulators such as vorinostat, and proteosome 
inhibitors such as bortezomib [2].
Epidermal growth factor receptor (EGFR) inhibitors are chemotherapeutic agents used for the 
treatment of specific cancer types. Rapidly developing acneiform eruption has been a hallmark 
of EGFR inhibitor therapy [49]. Based on previously published series, 60–100% of patients 
receiving EGFR inhibitor therapy develop acneiform eruptions [49–52]. Monoclonal antibod-
ies targeting EGFR, such as panitimumab, may also cause acneiform eruptions (Figure 2). 
Patients with a previous history of adolescent acne or folliculitis are more prone to acneiform 
eruptions and lesions commonly develop after the first cycle of therapy. Inflamed papules and 
pustules, accompanied by itching in seborrheic regions, are characteristic findings [3]. The devel-
opment of acneiform eruptions after the EGFR inhibitor therapy was suggested to be a prognostic 
factor indicating good treatment response [53]. Incidence and severity of acneiform eruption 
are dose-dependent. Tetracycline derivatives may be used to control severe lesions [3].
Tumor necrosis factor (TNF) inhibitors are particularly used for the treatment of autoimmune 
disorders and they may also induce acneiform eruptions. Among this class of drugs, inflix-
imab was the agent most frequently associated with acneiform eruptions [54]. The devel-
opment of acneiform eruptions was also reported in a male patient receiving adalimumab 
therapy due to Crohn’s disease [55]. In addition, lenalidomide, a thalidomide derivative, was 
demonstrated to be associated with acneiform eruptions due to its anti-TNF activity [56].
5. Treatment
Drug-induced acneiform eruptions are usually well tolerated. The most important step of 
treatment is identification of the causative drug and discontinuation of treatment, whenever 
possible. Conventional acne therapy may be used, if the treatment cannot be discontinued; 
however, treatment resistance is a common concern. Oral antibiotics such as doxycycline can 
be used in moderate and severe cases. In more severe cases, oral isotretinoin may also be used 
under close monitoring and by avoiding potential drug interactions [1].
Figure 2. Severe acneiform eruption on the chest during therapy with panitimumab for metastatic colon cancer.
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6. Conclusion
Drug-induced acneiform eruptions are frequently seen side effects, and it is difficult to pre-
vent them. It should be kept in mind that many drugs could cause drug-induced acneiform 
eruptions in clinical practice, and it is important to obtain a detailed history of drug use in 
suspected cases for appropriate follow-up and treatment approach.
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